Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XORTX TherapeuticsTSXV:XRTX 30 Buyback Yield % is -60.20 as of Aug. 02, 2026. GuruFocus rates TSXV:XRTX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 735 Biotechnology companies, XORTX Therapeutics ranks worse than 84.76% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
XORTX Therapeutics Buyback Yield % Historical Data
* Premium members only.
The historical data trend for XORTX Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:XRTX vs VRTX, REGN, RVMD: Buyback Yield % Comparison
For the Biotechnology subindustry, XORTX Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XORTX Therapeutics Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where XORTX Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XORTX Therapeutics (TSXV:XRTX) has a Buyback Yield % of -60.20 as of Aug. 02, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on XORTX Therapeutics and its competitors. According to the industry distribution chart, XORTX Therapeutics ranks #623 out of 735 companies in the Biotechnology industry, placing it in the top 84.8%.
Is XORTX Therapeutics' Buyback Yield % too high?
XORTX Therapeutics' current Buyback Yield % is -60.20. Based on the distribution chart, XORTX Therapeutics ranks #623 out of 735 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, XORTX Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does XORTX Therapeutics' Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, XORTX Therapeutics ranks #623 out of 735 companies for Buyback Yield %. This places XORTX Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on XORTX Therapeutics and its competitors. XORTX Therapeutics's current Buyback Yield % is -60.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XORTX Therapeutics stock overvalued right now?
XORTX Therapeutics (TSXV:XRTX) has a current Buyback Yield % of -60.20. The current Buyback Yield % is -60.20. XORTX Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For XORTX Therapeutics (TSXV:XRTX), the current Buyback Yield % is -60.20 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
30GF Score
Get the complete analysis for TSXV:XRTX
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:XRTX has been successfully added to your 
